secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001493152-24-036065
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics approves new equity plan and amended CEO/CFO employment deals
--------------------------------------------------------------------------------

- Board approved 2024 Omnibus Plan (subject to stockholder vote) with 1,600,000 shares available for future awards.
- Contingent option grants: CEO Huntsman 315,421 ISOs, CFO Amman 149,533 ISOs at $2.62/share, 3-year vesting.
- Amended employment agreements effective Jan 1, 2025 raise CEO base salary to $450,000 and CFO to $320,000.
- Severance: 12-month salary continuation on non-cause termination; 24 months after change-in-control; full equity vesting.
- New plan will replace 2019 Plan; unused shares retired if stockholders approve at 2024 Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224036065/0001493152-24-036065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224036065/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-036065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer